Pseudomonas aeruginosa virulence and antimicrobial resistance: Two sides of the same coin?

Critical Care Medicine

Volumn 42, Issue 1, 2014, Pages 201-202

  Hauser, Alan R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

antibiotic resistance; ExoU; fluoroquinolones; pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BRONCHITIS; EDITORIAL; HOST RESISTANCE; INNATE IMMUNITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 84891535095     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182a120cd     Document Type: Editorial

References (15)

1. Sato H, Frank DW: ExoU is a potent intracellular phospholipase. Mol Microbiol 2004; 53:1279-1290
2. Diaz MH, Hauser AR: Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 2010; 78:1447-1456
3. Diaz MH, Shaver CM, King JD, et al: Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 2008; 76:4414-4421
4. Feltman H, Schulert G, Khan S, et al: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147:2659-2669
5. Roy-Burman A, Savel RH, Racine S, et al: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-1774
6. El-Solh AA, Hattemer A, Hauser AR, et al: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157-1163
7. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008; 197:1079-1081
8. Rosenthal VD, Bijie H, Maki DG, et al: International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012; 40:396-407
9. Hsu DI, Okamoto MP, Murthy R, et al: Fluoroquinolone-resistant Pseudomonas aeruginosa: Risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005; 55:535-541
10. Wong-Beringer A, Wiener-Kronish J, Lynch S, et al: Comparison of type III secretion system virulence among fluoroquinolone-susceptible and-resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14:330-336
11. Zhu H, Conibear TC, Bandara R, et al: Type III secretion systemassociated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res 2006; 31:297-306
12. Garey KW, Vo QP, Larocco MT, et al: Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008; 20:714-720
13. Sullivan E, Bensman J, Lou M, et al: Risk of Developing Pneumonia Is Enhanced by the Combined Traits of Fluoroquinolone Resistance and Type III Secretion Virulence in Respiratory Isolates of Pseudomonas aeruginosa. Crit Care Med 2014; 42:48-56
14. Agnello M, Wong-Beringer A: Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoS One 2012; 7:e42973
15. El Solh AA, Akinnusi ME, Wiener-Kronish JP, et al: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008; 178:513-519